Aspirin with or without an antiemetic for acute migraine headaches in adults.
BACKGROUND
Migraine is a common, disabling condition and a burden for the individual, health services and society. Many sufferers choose not to, or are unable to, seek professional help and rely on over-the-counter analgesics. Co-therapy with an antiemetic should help to reduce nausea and vomiting commonly associated with migraine headaches.


OBJECTIVE
To determine the efficacy and tolerability of aspirin, alone or in combination with an antiemetic, compared to placebo and other active interventions in the treatment of acute migraine headaches in adults.


METHODS
We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford Pain Relief Database for studies through 10 March 2010.


METHODS
We included randomised, double-blind, placebo- or active-controlled studies using aspirin to treat a discrete migraine headache episode, with at least 10 participants per treatment arm.


METHODS
Two review authors independently assessed trial quality and extracted data. Numbers of participants achieving each outcome were used to calculate relative risk and numbers needed to treat (NNT) or harm (NNH) compared to placebo or other active treatment.


RESULTS
Thirteen studies (4222 participants) compared aspirin 900 mg or 1000 mg, alone or in combination with metoclopramide 10 mg, with placebo or other active comparators, mainly sumatriptan 50 mg or 100 mg. For all efficacy outcomes, all active treatments were superior to placebo, with NNTs of 8.1, 4.9 and 6.6 for 2-hour pain-free, 2-hour headache relief, and 24-hour headache relief with aspirin alone versus placebo, and 8.8, 3.3 and 6.2 with aspirin plus metoclopramide versus placebo. Sumatriptan 50 mg did not differ from aspirin alone for 2-hour pain-free and headache relief, while sumatriptan 100 mg was better than the combination of aspirin plus metoclopramide for 2-hour pain-free, but not headache relief; there were no data for 24-hour headache relief.Associated symptoms of nausea, vomiting, photophobia and phonophobia were reduced with aspirin compared with placebo, with additional metoclopramide significantly reducing nausea (P < 0.00006) and vomiting (P = 0.002) compared with aspirin alone.Fewer participants needed rescue medication with aspirin than with placebo. Adverse events were mostly mild and transient, occurring slightly more often with aspirin than placebo.


CONCLUSIONS
Aspirin 1000 mg is an effective treatment for acute migraine headaches, similar to sumatriptan 50 mg or 100 mg. Addition of metoclopramide 10 mg improves relief of nausea and vomiting. Adverse events were mainly mild and transient, and were slightly more common with aspirin than placebo, but less common than with sumatriptan 100 mg.
Kirthi
Varo
V
Pain Research and Nuffield Department of Anaesthetics, University of Oxford, West Wing (Level 6), John Radcliffe Hospital, Oxford, Oxfordshire, UK, OX3 9DU.
Derry
Sheena
S
Moore
R Andrew
RA
McQuay
Henry J
HJ
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000932:Antiemetics / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy*; D009325:Nausea / Q000188:drug therapy / Q000209:etiology; D020795:Photophobia / Q000188:drug therapy / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D018170:Sumatriptan / Q000627:therapeutic use; D014839:Vomiting / Q000188:drug therapy / Q000209:etiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000932:Antiemetics; D018170:Sumatriptan; D008787:Metoclopramide; D001241:Aspirin
Cephalalgia. 2008 Sep;28 Suppl 2:28-35
18715330
Eur J Clin Pharmacol. 1983;24(6):777-85
6884416
J Clin Pharm Ther. 2009 Apr;34(2):177-86
19250138
Eur Neurol. 1999 Jan;41(1):37-43
9885327
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
BMJ. 2004 Dec 11;329(7479):1369-73
15550401
Value Health. 2009 Jan-Feb;12(1):55-64
18671771
Pharmacoeconomics. 1997;11 Suppl 1:1-10
10168038
J Fam Pract. 1996 Jan;42(1):36-42
8537803
Pain. 1998 Dec;78(3):209-216
9870574
Can J Neurol Sci. 1993 May;20(2):131-7
8334575
Cephalalgia. 2000 Nov;20(9):765-86
11167908
Eur J Neurol. 2009 Sep;16(9):968-81
19708964
Headache. 1994 Jun;34(6):337-43
7928312
J Neurol. 2007 Jun;254(6):705-12
17406776
Br Med J. 1974 Nov 2;4(5939):265-8
4425854
Cephalalgia. 1994 Aug;14(4):297-300
7954760
Cephalalgia. 2004 Nov;24(11):947-54
15482357
Br Med J (Clin Res Ed). 1988 May 7;296(6632):1313-6
3133061
Presse Med. 1995 Feb 4;24(5):254-8
7899379
Headache. 2002 Apr;42(4):249-55
12010380
BMJ. 1995 Feb 18;310(6977):452-4
7873954
Br J Clin Pharmacol. 1975 Feb;2(1):57-63
791318
Cephalalgia. 1984 Jun;4(2):107-11
6375873
Headache. 2005 Apr;45(4):283-92
15836564
BMJ. 1997 Sep 13;315(7109):635-40
9310564
Pharmacoeconomics. 1998 Jun;13(6):667-76
10179702
Ann Intern Med. 1987 Aug;107(2):224-33
3300460
Arch Intern Med. 1999 Apr 26;159(8):813-8
10219926
Arch Intern Med. 1999 Apr 26;159(8):857-63
10219932
Pain. 2002 Jun;97(3):247-257
12044621
Expert Rev Neurother. 2006 Apr;6(4):563-73
16623655
Rev Neurol. 2008 Nov 16-30;47(10):506-8
19012253
Cephalalgia. 2005 Oct;25(10):776-87
16162254
Headache. 2007 Mar;47(3):355-63
17371352
Neurology. 2007 Jan 30;68(5):343-9
17261680
Acta Neurol Belg. 2007 Sep;107(3):84-90
18072336
QJM. 1996 Jan;89(1):77-84
8730346
Headache. 2008 Apr;48(4):601-5
18377382
Cephalalgia. 1988;8 Suppl 7:1-96
3048700
Cephalalgia. 2000 Sep;20(7):663-7
11128825
Lancet. 1995 Oct 7;346(8980):923-6
7564725
Cephalalgia. 1995 Dec;15(6):531-5
8706118
Neurology. 2008 Aug 19;71(8):559-66
18711108
Headache. 2006 May;46(5):715-25
16643573
Headache. 2009 Jan;49(1):79-89
19125877
Eur Neurol. 1980;19(3):163-5
7389761
Pain. 1996 Aug;66(2-3):239-46
8880846
Eur Neurol. 1992;32(3):177-84
1317294
Cephalalgia. 1994 Apr;14(2):156-61
8062355
Nat New Biol. 1971 Jun 23;231(25):232-5
5284360
Curr Opin Neurol. 2008 Jun;21(3):331-7
18451718
Cephalalgia. 2004;24 Suppl 1:9-160
14979299
Eur Neurol. 1999;41(2):88-93
10023111
BMJ. 2000 Nov 11;321(7270):1183-7
11073508
Eur Neurol. 2004;52(1):50-6
15240983
Eur Neurol. 2002;47(2):88-98
11844897